­
­
­
­

Inventi Impact - NDDS

Patent Watch

  • Peelable pouch for transdermal patch and method for packaging

    A peelable pouch comprises a substantially flat enclosure formed by first and second opposing flexible plies. A seal extends along at least a portion of a perimeter of the opposing plies. A flat, flexible transdermal patch is disposed in the enclosure and includes a bioactive agent dissolved in a layer of adhesive. A release liner is removably attached over the layer of adhesive, with the patch and the release liner together being sufficiently resilient so as to generate a spring force when displaced out of the flat configuration. The first and the second plies each being separable along the seal and displaceable out of the flat configuration. The spring force generated by the patch and the release liner being sufficient to overcome an adhesive force created by the adhesive between the patch and one of the plies.

  • Inhaler system for targeted maximum drug-aerosol delivery

    A smart inhaler system comprising an inhaler device for directed aerosol delivery facilitated by an adaptive nozzle and a mechanism for inhalation waveform modulation is provided. Methods of using the smart inhaler system for delivering an active agent to a target area of a lung of a subject are further provided.

  • Biodegradable biocompatible implant and method of manufacturing same

    Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally occurring biomaterial, chitosan, or a mixture of chitin and chitosan. The lipid component may include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidyl or a mixture thereof. The delivery system may be used for delivery of hydrophilic agents, hydrophobic agents or combinations thereof. The therapeutically active agents may be formulated within the matrix as free agents or incorporated into particles. In a preferred embodiment the agents are incorporated into polymeric particles that are dispersed throughout the matrix.

  • Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

    Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature T.sub.m of at least 20.degree. C. above the recommended storage temperature (Tst) for drug delivery.

  • Biointerface membranes incorporating bioactive agents

    A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

  • Drug delivery system

    A drug delivery system is disclosed which may be a throwaway or reusable device for delivery at least one drug to a patient. Also described is a method for administering a drug using said device and a packaged drug for use with said device. The drug delivery device (10) comprises a housing (12), a means (14) for generating a force capable of pushing a drug (16) from a packaging (18) into a human or animal body, a means (20) for transmitting said force to push the drug (16) from the packaging (18) into the human and animal body, and a means (38, 42b) for triggering the device. Where the device is a single use drug delivery system, a packaged drug (100) forms an integral part of the device. The packaged drug comprises a region (102) allowing it to be slidably mounted to the drug delivery device (10).

  • Method of manufacturing a drug delivery system

    A method of manufacturing a drug delivery system uses gas cluster ion beam irradiation on an outer surface of a member to determine one or more characteristics of the drug delivery system.

  • Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device

    Featured are devices for delivering a treatment medium to an eye as well as methods related thereto. Such devices and methods allow a desired amount of the treatment medium to be delivered in a controllable manner over a predetermined time period. In particular embodiments, the delivery device is configured and arranged so the treatment medium is eluted from one portion of the delivery device and so that another portion thereof is removably secured within a natural opening or orifice in or proximal to the eye. In specific embodiments the another portion is configured and arranged so as to be removably secured within the natural opening comprising at least one punctum of an eye.

  • Implantable stimulator

    An implantable stimulator includes a tube assembly that is configured to house a number of components that are configured to apply at least one stimulus to at least one stimulation site within a patient. The tube assembly has a shape that allows the stimulator to be implanted within said patient in a pre-determined orientation. Exemplary methods of stimulating a stimulation site within a patient include applying an electrical stimulation current to a stimulation site via one or more electrodes extending along one or more sides of a stimulator. The stimulator has a shape allowing the stimulator to be implanted within the patient in a pre-determined orientation.

  • Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

    This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1.times.10.sup.-7 reciprocal second.

  • Medical device for controlled drug delivery and cardiac monitoring and/or stimulation

    Medical device and methods are provided for controlled drug delivery in a cardiac patient. The device includes an implantable drug delivery module comprising reservoirs containing a drug and a control means for selectively releasing an effective amount of drug from each reservoir; one or more electrodes or sensors for cardiac monitoring, stimulation, or both; and a microcontroller for controlling operational interaction of the drug delivery module and the cardiac electrode. The electrodes may comprise ECG monitoring, cardioversion, or cardiac pacing electrodes. A medical device also is provided for controlled delivery of drug to a patient having congestive heart failure, which includes an implantable drug delivery module comprising a natriuretic peptide and a release mechanism for selectively releasing a pharmaceutically effective amount of the natriuretic peptide into the patient; and a microcontroller for controlling the release mechanism, for example, in response to one or more monitored patient parameters.

  • Method and apparatus for selective material delivery via an intra-renal catheter

    Two renal delivery members have two distal ports that are adapted to be positioned within two renal arteries via their corresponding renal ostia at unique locations along an abdominal aortic wall. A proximal coupler assembly is outside the body and is coupled to deliver material to the two distal ports for bi-lateral renal therapy. One or both of the delivery members may be self-cannulating into the corresponding renal ostium, or may be controllably steered into the respective ostium. Non-occlusive anchors may be coupled with one or both of the delivery members at anchoring positions in the renal artery or abdominal aorta to secure the renal delivery member within the renal artery. Renal-active fluid agents are coupled to the bi-lateral delivery system. Another renal therapy system cannulates a renal vein from the vena cava and controls a retrograde delivery of agents to the respective kidney.

  • Hybrid device for cell therapies

    A device for receiving implanted biological material includes a porous outer wall defining an inner space, a fluid manifold assembly for selectively infusing at least one of immunosuppressive and growth factor media to said space, and a pump structure operatively coupled to the manifold assembly. The device may comprise an additional plunger body for being disposed in said space and so as to define a peripheral gap between the plunger and the perforated wall of the device.

  • Conveniently implantable sustained release drug compositions

    This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

  • PH modulated films for delivery of actives

    The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

  • Dermal application system for aminolaevulinic acid

    The invention relates to a dermal for aminolaevulinic acid, wherein a self-adhesive matrix system is used containing crystalline aminolaevulinic acids.

  • Device and methods of sequential, regional delivery of multiple cyctotoxic agents and directed assembly of wound repair tissues

    An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the preferred form of a blend of high molecular weight hyaluronic acid conjugated with a second cytotoxic agent in the preferred form of paclitaxel and of pure high molecular weight hyaluronic acid is invested in the void spaces. Thus, when implanted, the paclitaxel and cisplatin are released sequentially, each initially at high level concentrations followed by lower release. Radiotherapy can be begun after the release of the paclitaxel has been completed but while the cisplatin is being released.

  • Hollow nanoparticle of NBsAg large protein for drug delivery

    The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.

  • Infusion set self-occlusion mechanism

    A device, system and method for occluding fluid flow through an infusion set detached from a patient's body. The device includes a means for detecting loss of contact to a patient's body and activating an occlusion mechanism accordingly.

  • pH-sensitive polymeric micelles for drug delivery

    Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of treating a warm-blooded animal with such a drug are disclosed.

  • Biodegradable polyketal polymers and methods for their formation and use

    The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations. A method for forming the chiral polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a suitable reagent to form the chiral polyketal. A method for use in chiral separations includes the incorporation of the chiral polyketals in the mobile phase during a chromatographic separation, or into chiral stationary phases such as gels. The present invention further relates to chiral polyketals as a source for chiral compounds, and methods for generating such chiral compounds.

  • Resorbable anchor arrangements for implantable devices and methods of making and using

    An implantable device includes a device body and at least one anchoring unit configured and arranged for anchoring the device body in a patient upon implantation. The anchoring unit includes a resorbable material that resorbs into the patient over a period of time after implantation.

  • Inhalable epinephrine

    The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.

  • Systems and methods for intra-oral diagnosis

    Devices, systems, and methods are disclosed for intra-orally diagnosing a body condition.

  • Effervescent powders for inhalation

    Effervescent powders comprising inhalable particles are disclosed, as are methods for preparing these powders. The inhalable carrier particles comprise an inorganic or organic carbonate, and an acid, and exhibit effervescence when exposed to water or humid air. The particles have a mass median aerodynamic diameter suitable for nasal, bronchial, or pulmonary administration. The inhalable particles may be used as carriers for active agents. The inhalable particles may also be used to enhance permeability of mucosal and surface barriers on an inner surface of the nose, mouth, airway, and/or lungs of a patient, as well as to loosen, thin, cleanse, and remove mucus and extrinsic surface materials from an inner surface of the nose, mouth, airway, and/or lungs of a patient in need thereof.

  • Iontophoretic drug delivery system

    The iontophoretic drug delivery system includes electrodes controlled by a microprocessor controller to drive charged molecules contained in a drug reservoir through the skin into the issues of a patient. The iontophoretic drug delivery system further includes an antenna connected to the programmable microprocessor. The antenna allows for the programming of the microprocessor and for the exchange of patient, drug, and treatment related information between the microprocessor and an external device. The iontophoretic drug delivery system is also provided with buttons to allow a patient to manually activate the drug delivery system. The iontophoretic drug delivery system is housed within a thin polyester film membrane.

  • Needleless syringe using supersonic gas flow for particle delivery

    A needleless syringe having a membrane (28) which is ruptured by gas pressure to generate a supersonic gas flow in which particles containing a therapeutic agent are injected.

  • Polymalic acid-based multi-functional drug delivery system

    A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.

  • Miniature pump for drug delivery

    A miniature drug delivery pump utilizes a shape memory Ni--Ti alloy. A flow restrictor is provided and the pump is refillable.

  • Drug delivery cassette and a medical effector system

    Disclosed is an interface between a drug delivery cassette and a medical effector system. The cassette may be mounted to the medical effector system in such a way that a fluid tube located on the cassette is positioned adjacent to a pump located on the medical effector system. The medical effector system may purge the fluid line of air by activating the pump and forcing fluid through the fluid line until a sensor positioned to monitor the fluid line indicates that fluid and not air is present in the tube. To prevent air purging of the fluid tube when connected to the patient, the medical effector system prohibits air purging unless the drug delivery end portion of the fluid tube is in a designated storage site located on the cassette. This is accomplished with a position sensor at the storage site that monitors the position of the fluid tube.

  • Osteochondral repair using plug fashioned from whole distal femur or condyle formed of hydrogel composition

    A method and apparatus for repairing isolated chondral defects using synthetic implants. Lesions in articular tissue are corrected by forming a recipient socket in the tissue. A donor graft of a size corresponding to the recipient socket is harvested from a synthetic specimen made of a synthetic tissue material, such as poly (vinyl) alcohol hydrogel. The donor graft is implanted into the recipient socket.

  • Bioprosthetic tissue preparation with synthetic hydrogels

    Methods for treating xenogenic tissue for implantation into a human body including in-situ polymerization of a hydrogel polymer in tissue, and tissue treated according to those methods, where the polymerization takes place in tissue that has not been fixed with glutaraldehyde. The polymerization may only fill the tissue, bind the polymer to the tissue, or cross-link the tissue through the polymer, depending on the embodiment. One method includes free radical polymerization of a first vinylic compound, and can include cross-linking through use of a second compound having at least two vinyl groups. Another method utilizes nucleophilic addition polymerization of two compounds, one of which can include PEG and can further include hydrolytically degradable regions. In one embodiment, applicants believe the in-situ polymerization inhibits calcification, and that the polymerization of tissue un-fixed by glutaraldehyde allows for improved penetration of the polymer. The methods find one use in the treatment of porcine heart valve tissue, intended to extend the useful life of the valves by inhibiting calcification. The incorporation of degradable hydrogel regions may initially fill the tissue and reduce any initial inflammatory response, but allow for later infiltration by cells to remodel the tissue.

  • Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects

    The present application is directed to compositions and methods for mechanically controlling the bleeding of bone. The compositions comprise in intimate admixture the following Components 1, 2 and 3: (1) a finely powdered, carboxylic acid salt comprising a carboxylate anion and a metallic cation, (2) a composition comprising pyrrolidone or an N-alkyl pyrrolidone wherein alkyl is a C1-C12 alkyl radical and an optional, biocompatible liquefying agent if the composition is in solid form at room temperature, and (3) an optional analgesic, wherein the analgesic is present in a free base and salt form.

  • Methods and Devices for Programmable Delivery of Microdoses of Liquid Drugs

    Devices of this invention include replaceable cartridges for delivery of doses of fluids. Cartridges having a fluid supply reservoir comprising an expandable element are designed to be connected with non-disposable actuating module supplied with a sensor, a mechanism to apply a force to the fluid, thereby forcing a predetermined dose out of the reservoir, and a processor providing control outputs from a sensor system according to preprogrammed instructions. Methods of this invention include delivery of microdoses of fluids using devices of this invention.

  • Safety Drug Delivery System

    Drug delivery systems are provided that include an actuator assembly permanently attached to a filter for connection of a container containing medications such as epidural anesthesia, to a delivery site. In one or more embodiments, the actuator assembly includes a projection with an opening extending from a distal end of the actuator assembly in a proximal direction and the filter includes an inlet and an outlet in fluid communication with the opening. The filter includes a housing including two plates joined together or a cylindrical body defining a cavity containing filter materials. A conduit may be attached to the outlet of the filter to allow connection of the drug delivery systems described to a delivery site, such as a catheter. Methods of administering a medication to a delivery site are also provided.

  • TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

    A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater.

  • METHODS, COMPOSITIONS AND SYSTEMS FOR LOCAL DELIVERY OF DRUGS

    Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.

  • INTRACOCHLEAR DRUG DELIVERY TO THE CENTRAL NERVOUS SYSTEM

    The present invention is directed to method and system for delivery of brain-targeted drugs to the cerebrospinal fluid via the perilymphatic fluid of the inner ear. The system utilizes the passage of cochlear aqueduct as a drug delivery route from the inner ear to the subarachnoid space of the brain. The delivery system includes an otological conduit which enables transfer of drugs from the auditory ear canal to the inner ear and a wearable dispenser for supplying drugs to the otological conduit. The drug composition comprises a suspension of solid lipid nanoparticles (SLN) which facilitate delivery through the cochlear aqueduct. Employing aspects of present invention, a method and system for treating chronic pain is described.

  • Pressure Sensing in Implantable Medical Devices

    An implantable medical device for delivering a therapeutic substance to a delivery site in a patient. A reservoir holds a supply of the fluid therapeutic substance. A catheter has a proximal end, a delivery region and a lumen extending from the proximal end to the delivery region. The proximal end of the catheter is operatively coupled to the reservoir. The delivery region of the catheter is adapted to be placed proximate the delivery site in the patient. The therapeutic substance is adapted to be delivered through the lumen to the patient. A sensing device is operatively coupled with the lumen of the catheter being capable of detecting a pressure of the therapeutic substance in the lumen. A controller is operatively coupled to the sensing device, the controller being capable of taking an action in response to the pressure in the lumen.

  • WATER INSOLUBLE POLYMER: STARCH-BASED FILM COATINGS FOR COLON TARGETING

    A controlled release delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: at least a water insoluble polymer and a starch composition including at least one component selected from the group consisting of a starch having an amylose content of between 20 and 45%, a modified starch having an amylose content of between 50 and 80% and a legume starch. The present invention also relates to the use and method for making the same.

  • TREATMENT MEDIUM DELIVERY DEVICE AND METHODS FOR DELIVERY OF SUCH TREATMENT MEDIUMS TO THE EYE USING SUCH A DELIVERY DEVICE

    A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.

  • DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF

    Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO.sub.2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO.sub.2 in their environment, thus regulating release of an entrapped drug.

  • Drug Delivery After Biodegradation Of The Stent Scaffolding

    Disclosed herein is a stent comprising: a bioabsorbable polymeric scaffolding; and a coating comprising a bioabsorbable material on at least a portion of the scaffolding, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the coating.

  • TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

    A formulation for transdermal or transmucosal administration of an active agent. The formulation includes an active agent and a delivery vehicle comprising a C.sub.2 to C.sub.4 alkanol, a polyalcohol, and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces. The formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters in order to avoid undesirable odor and irritation effects caused by such compounds during use of the formulation. Also, the active agent is testosterone that is present in an amount of about 1%, the alkanol is ethanol that is present in an amount of about 46.28% to about 47.5% of the formulation; the polyalcohol is propylene glycol that is present in an amount of about 6% of the formulation; and the permeation enhancer is diethylene glycol monoethyl ether that is present in an amount of about 5% of the formulation.

  • Sensing and interactive drug delivery

    An interactive drug delivery system includes a drug delivery module, an optical probe, a local controller, and an optional central controller. The drug delivery module is constructed and arranged to deliver selected amounts of a drug into a subject. The optical probe is constructed and arranged to detect in a selected tissue region of the subject a manifestation caused by the delivered drug. The local controller is constructed and arranged to receive data from or transmit data to the optical probe and the drug delivery module. The local controller is arranged to correlate optical data, received from the optical probe, to selected data and provide signals to the drug delivery module for adjusting the amounts of the drug to be delivered into the subject.

  • LUNG TARGETING DUAL DRUG DELIVERY SYSTEM

    The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.

  • PARTIALLY MICROCELLULAR, SELECTIVELY HYDROPHILIC COMPOSITE CONSTRUCT FOR OCULAR DRUG DELIVERY

    A partially microcellular, selectively hydrophilic composite as a self-standing construct or a component of a device for ocular delivery of at least one bioactive agent, the composite comprising a highly hydrophilic microcellular foam adjoined with a flexible hydrophobic barrier polymeric film.

  • Drug Delivery After Biodegradation Of The Stent Scaffolding

    Disclosed is a stent comprising a bioabsorbable polymeric scaffolding; and a plurality of depots in at least a portion of the scaffolding, wherein the plurality of depots comprise a bioabsorbable material, wherein the degradation rate of all or substantially all of the bioabsorbable polymer of the scaffolding is faster than the degradation rate of all or substantially all of the bioabsorbable material of the depots.

  • NOVEL GASTRORETENTIVE DELIVERY SYSTEM

    A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient. The said system is based on the use of three different gastroretentive mechanisms: flotation, swelling and mechanical strength, the three mechanisms acting in a complimentary way. Processes for manufacturing same and methods of treatment are also disclosed.

  • HIGH SHEAR APPLICATION IN DRUG DELIVERY

    In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.

  • Active transdermal drug delivery system and the method thereof

    The present invention relates to an active transdermal drug delivery system performing transdermal drug delivery comprising of a patch capable of being attachable to the skin of the subject; at least one electrical energy power input; a plurality of converters/energy transducers configured for converting the electrical energy to different forms of energy; and a controller including a programmable microprocessor configured for providing the intensity, sequence, nature, and timing information for the different energies supplied and thereby providing activating signals to the said converters for the transdermal drug delivery by the said patch, and a method for performing transdermal drug delivery using said electronic patch.

  • TRANSDERMAL DELIVERY PATCH

    A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

  • THERAPEUTIC AGENT DELIVERY DEVICE FOR DELIVERY OF A NEUROTOXIN

    A therapeutic agent delivery device and method for eluting a therapeutic agent to a target location are disclosed. The therapeutic agent delivery device may comprise a first conductive element, a second conductive element, and an electrochemical layer including a neurotoxin located between the first conductive element and the second conductive element. The first conductive element and the second conductive element are adapted to be connected to a voltage source. When the first conductive element and the second conductive element are connected to the voltage source, an electrochemical reaction occurs causing the neurotoxin to release from the electroactive layer and elute to a target location.

  • DELIVERY PARTICLES

    The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities.

  • FLEXIBLE STENT HAVING PROTRUDING HINGES

    The present invention relates to tissue-supporting medical devices and drug delivery systems, and more particularly to tubular flexible stents that are implanted within a body lumen of a living animal or human to support the organ, maintain patency and/or deliver drugs or agents. The tubular flexible stent has a cylindrical shape defining a longitudinal axis and includes a helical section having of a plurality of longitudinally oriented strut members and a plurality of circumferentially oriented hinge members connecting circumferentially adjacent strut members to form a band. The band is wrapped about the longitudinal axis in a substantially helical manner to form a plurality of helical windings. At least one connector member extends between adjacent windings.

  • TRANSDERMAL PHARMACEUTICAL PREPARATION AND ADMINISTRATION OF TIROFIBAN

    The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.

  • Water Dispersible Glyceryl Monooleate Magnetic Nanoparticle Formulation

    The present invention is an aqueous dispersible magnetic nanoparticle formulation with a high drug loading capacity used for sustained drug delivery. The formulated magnetic nanoparticles are composed of an iron oxide core coated with a long chain polymer, which provides aqueous dispersibility without the use of surfactant. A method is developed for the functionalization of magnetic nanoparticles for use in biomedical field.

  • PRODUCING COMPOSITE NANOPARTICLES CONTAINING ORGANIC IONS

    A method for producing a composite nanoparticle, including the steps of, collapsing at least a portion of a polyelectrolyte polymer in solution about one or more precursor moieties to form a composite precursor moiety having a mean diameter in the range between about 1 nm and about 100 nm, wherein the polyelectrolyte polymer has an extended conformation in a first solution state and a more compact conformation in a second solution state; and cross-linking the polyelectrolyte polymer of the composite precursor moiety to form a composite nanoparticle wherein the precursory moiety is a charged organic ion.

  • Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition

    The present invention relates to a nano-carrier for an anticancer drug, which comprises: a metal nanoparticle; and a polynucleotide for connecting with an anticancer drug having a pyrimidine group or a purine group, wherein the polynucleotide connects to a surface of the metal nanoparticle, and the anticancer drug binds to the polynucleotide through the pyrimidine group or the purine group. In addition, the present invention also provides a complex of an anticancer drug and a nano-carrier, a pharmaceutical composition thereof, a method for manufacturing the complex, and a method for treating a cancer by using the pharmaceutical composition.

  • NANOPARTICLE FORMULATED GLYCOLIPID ANTIGENS FOR IMMUNOTHERAPY

    A composition for stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells includes a glycolipid antigen and a nanoparticle conjugated with the glycolipid antigen. The glycolipid antigen and the nanoparticle are not antigenic in mouse and human being. The composition can further include covalent or non-covalent connection between the glycolipid antigen and the nanoparticle. The glycolipid antigen is alpha-galactosylceramide or an analog of that. The nanoparticle can be a polymer. A production method of the composition includes preparing a nanoparticle and a glycolipid antigen and loading the glycolipid antigen to the nanoparticle. The glycolipid antigen can be coated onto the surface of the nanoparticle or encapsulated within the nanoparticle. A method of stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells is also provided.

  • Iontophoretic Drug Delivery Packaging

    The present invention relates generally to iontophoretic drug delivery systems for transdermal delivery of therapeutic agents and, more particularly, to packaging such systems for long shelf life and easy assembly for use. The system package includes an iontophoretic skin worn patch component that accommodates a power source, electronics, electrodes and a drug pack component that carries a therapeutic agent which is contained as a separate sealed component. The packaged system further provides for ease of assembly at the time of use.

  • METHODS FOR REDUCING OR NEOVASCULARIZATION OR EDEMA

    Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

  • FUNCTIONALIZED NANOPARTICLE, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF

    The present invention relates to a new type of functionalized nanoparticles for drug delivery, comprising a type of polymer nanoparticles, a polymer stabilizer coating, and a drug, wherein said polymer stabilizer coating is coated on the surface of said type of polymer nanoparticles, and said drug is conjugated to said polymer stabilizer coating. The present invention also relates to a method for preparing the nanoparticles; and provides a method for treating an ischemic or degenerative disease, comprising administrating an effective amount of the type of functionalized nanoparticles to a subject.

  • Implantable Pressure-Actuated Drug Delivery Systems and Methods of Manufacture and Use

    Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.

  • NOVEL FORMULATION FOR TREATING FUNGAL INFECTIONS

    A novel formulation for treating fungal infections comprising Cholesterol containing Nanosomal Amphotericin B in a Saline Suspension

  • Chirally Correct Retinal Cyclodextrin Acetals for Clarifying Skin Complexion

    The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof; ##STR00001##

  • TRANSMUCOSAL DELIVERY SYSTEM

    This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.

  • Systems, devices, and methods including implantable devices with anti-microbial properties

    Systems, devices, methods, and compositions are described for providing an actively controllable implant configured to, for example, monitor, treat, or prevent microbial growth or adherence to the implant.

  • Cartridge and Medication Delivery Device

    A single-use cartridge for a medication delivery device, comprises a body element (1) having a proximal end and a distal end, a dispensing means (5), and a deformable capsule (3) containing medication. The capsule (3) is disposed inside the body element (1) and has a skin which encases the medication. The capsule (3) is configured to be pushed in the distal direction against the dispensing means (4) so that the content of the capsule (3) is dispensed.

  • MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH

    The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

  • ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS

    The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals.

  • DRUG DELIVERY BY CARBON NANOTUBE ARRAYS

    The invention generally relates to carbon nanotube based drug delivery methods, devices, and compositions. More particularly, the invention relates to controlled drug delivery using anchored carbon nanotube arrays.

  • Compositions and Methods for Targeted Thermomodulation

    Provided are nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans.

  • TOUCH-ACTUATED MICROPUMP FOR TRANSDERMAL DRUG DELIVERY AND METHOD OF USE

    A micropump device. The micropump device includes a first layer forming a first chamber configured to store a working material, a second chamber defined by a deflectable membrane in fluid communication with the first chamber and configured to deflect in response to a pressure increase in the first chamber in response to a volume increase in the first chamber, the second chamber configured to store a drug compound to be delivered to a subject's vascular system, and at least one needle in fluid communication with the second chamber and configured to penetrate a subject's skin to pump the drug compound in response to the deflection of the deflectable membrane.

  • ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY

    The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4'-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment

  • Oral Drug Delivery System

    Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

  • Oral Drug Delivery System

    Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

  • Multi-Dose Drug Delivery Device and Method

    Drug delivery devices and methods are provided. The device included two or more housing units connected together end-to-end in a fixed, linear orientation, the exterior surfaces of the connected housing units defining a sidewall of the device; discrete drug dose units disposed within the housing units; degradable timing members connected to the housing units and separating the discrete dose units from one another; first and second end pieces defining opposed ends of the device such that the discrete dose units are located between the first and second end pieces within each of the housing units, wherein the device is configured to release in vivo a first of the discrete dose units following rupture of the first or second end piece, and subsequently to release in vivo a second of the discrete dose units following rupture of the degradable timing member separating the first discrete dose unit from the second discrete dose unit.

  • THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM

    The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.

  • DAMPING SYSTEMS FOR STABILIZING MEDICATIONS IN DRUG DELIVERY DEVICES

    The invention relates to systems and methods for stabilizing therapeutic formulations used in medical devices. In particular, the invention relates to systems designed to inhibit the aggregation of therapeutic molecules such as polypeptides stored within a medication delivery device, for example polypeptide aggregation that can result from jostling the medication within a fluid medication reservoir. In embodiments of the invention, a damping system is operably connected to a fluid medication reservoir that is disposed within the housing of a device so as to inhibit the agitation of a fluid medication. Typically the damping system comprises one or more energy absorbing materials.

  • AQUEOUS DRUG DELIVERY SYSTEM

    Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.

  • Devices And Methods For Engaging Indexed Valve And Pressurized Canister Assembly With Collar And For Linear Actuation By Plunger Assembly Into Fluid Communication With Device For Regulating Drug Delivery

    A valve assembly comprising a housing and a valve, the valve being disposed within the housing, a first indexed member integral to the housing, the first indexed member adapted to be complementary to a second indexed member, and a radio frequency identification device adapted to communicate with a radio frequency receiver, the valve being configured to align with a canister, seal the canister and open in a single movement. A drug containment device having said valve assembly is also disclosed.

  • Devices And Methods For Engaging Indexed Valve And Pressurized Canister Assembly With Collar And For Linear Actuation By Plunger Assembly Into Fluid Communication With Device For Regulating Drug Delivery

    An indexed drug delivery device (70) comprising a valve assembly (13) comprising a housing (26) and a valve, the valve disposed within the housing, one or more keys (34,38) integral to the housing, the keys complementary to corresponding openings on a collar (12), a pressurized canister (28) in fluid communication with the valve assembly, the canister containing an active pharmaceutical ingredient and an inactive carrier gas, a receiving assembly comprising a receptacle adapted to engage at least a portion of the housing, a seat adapted to engage the valve, and, a plunger assembly adapted to linearly actuate the valve assembly and canister along an axis and to engage the valve and seat, the plunger assembly comprising a carriage fixed to the collar, and, a lever having a cam adapted to engage a spring, the spring adapted to linearly actuate the carriage, valve assembly, canister and collar along the axis.

  • Dry Powder Drug Delivery Formulations, Methods of Use, and Devices Therefore

    The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).

  • STIMULI-RESPONSIVE SYSTEMS FOR CONTROLLED DRUG DELIVERY

    A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

  • Liposome Having Inner Water Phase Containing Sulfobutyl Ether Cyclodextrin Salt

    A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether .alpha.-cyclodextrin, sulfobutyl ether .beta.-cyclodextrin, or sulfobutyl ether .gamma.-cyclodextrin.

  • Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes

    A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

  • METHOD OF MAKING LIPOSOMES, LIPOSOME COMPOSITIONS MADE BY THE METHODS, AND METHODS OF USING THE SAME

    A method of preparing liposomes, liposome compositions formed by the process, and methods of using the liposome composition are provided herein.

  • LIPOSOME-ENCAPSULATED GLUTATHIONE FOR ORAL ADMINISTRATION

    The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

  • Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome

    An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

  • ASSEMBLY FOR A DRUG DELIVERY DEVICE AND DRUG DELIVERY DEVICE

    An assembly for a drug delivery device comprises a housing having a proximal end and a distal end, a dose button configured to be moved with respect to the housing for setting and delivering a dose of a drug, and a resilient setting member. For a dose delivery movement, the dose button is arranged to be moveable in the distal direction with respect to the housing from a dose delivery position, thereby deforming the resilient setting member to store energy in the resilient setting member. The assembly is configured to use the energy stored in the resilient setting member for a dose setting movement to move the dose button in the proximal direction with respect to the housing into the dose delivery position. Furthermore, a drug delivery device is provided.

  • SOLID DRUG DELIVERY APPARATUS AND FORMULATIONS AND METHODS OF USE

    Embodiments provide apparatus and methods for delivering solid form medications such as pellets to various locations in the body. One embodiment provides an apparatus for in vivo delivery of medication pellets comprising a first chamber including an opening; a second chamber substantially surrounding the first chamber, a carriage disposed in the first chamber, a mechanism for transferring the medication pellets from the first chamber to the second chamber and a pusher plate. The carriage can hold and dispense a plurality of medication pellets. Each pellet contains a selected dose of drug to treat a medical condition. A catheter is positioned in the second chamber. The catheter has a lumen sized for the pellet, a proximal end inside the chamber and a distal end extending through chamber opening to deliver the pellet to a delivery site. The pusher plate engages and advances the pellet though the catheter to the delivery site.

  • DRUG DELIVERY SYSTEM USING HYALURONIC ACID-PEPTIDE CONJUGATE MICELLE

    The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.

  • TARGET-AIMING DRUG DELIVERY SYSTEM FOR DIAGNOSIS AND TREATMENT OF CANCER CONTAINING LIPOSOME LABELED WITH PEPTIDES WHICH SPECIFICALLY TARGETS INTERLEUKIN-4 RECEPTORS, AND MANUFACTURING METHOD THEREOF

    The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors. Therefore, the liposome which contains anticancer drugs labeled with IL4Pep peptides of the present invention can be applied, as the target-aiming drug delivery system, effectively to the diagnosis and treatment of cancers.

  • Method and Assembly for a Drug Delivery Device

    A method for securing a cartridge (4) in a cartridge holder (3) is provided, the method comprising the steps of inserting the cartridge (4) into the cartridge holder (3), the cartridge holder (3) having a proximal end and a distal end, axially displacing the cartridge (4) in a proximal direction with respect to the cartridge holder (3) from a distal initial position to a proximal end position and securing the cartridge (4) in the end position against displacement in the distal direction with respect to the cartridge holder (3). An assembly for a drug delivery device (1) is provided comprising a cartridge (4), an adjusting member (12, 25, 28, 34) and a cartridge holder (3). The cartridge holder (3) has a distal end and a proximal end. The adjusting member (12, 25, 28, 34) is secured to the cartridge holder (3). The adjusting member (12, 25, 28, 34) holds a distal portion of the cartridge (4) at a distance with respect to a distal portion of the cartridge holder (3).

  • SYSTEM AND METHODS FOR OPTIMIZED DRUG DELIVERY AND PROGRESSION OF DISEASED AND NORMAL CELLS

    System for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

  • Assembly and Piston Rod for a Drug Delivery Device

    A drive mechanism for a drug delivery device (1) comprises a housing (2), a drive member (5) and a piston rod assembly (32). The drive member (5) is configured to be axially displaced in a dose setting direction with respect to the housing (2) for setting a dose of a drug (24) and to be axially displaced in a dose delivery direction with respect to the housing (2) for delivering the set dose of the drug (24). The drive member (5) comprises a drive feature (15). The piston rod assembly (32) comprises a set of interaction surfaces (17) for mechanical interaction with the drive feature (15), with at least two interaction surfaces (17) being axially and angularly offset with respect to each other. When the drive member (5) is displaced in the dose delivery direction for delivering the set dose, the drive feature (15) mechanically interacts with one of the interaction surfaces (17) and the piston rod assembly (32) rotates with respect to the housing (2), thereby rotating and axially displacing another one of the interaction surfaces (17) from a non-interaction position into an interaction position in which the drive feature (15) may interact with the other one of the interaction surfaces (17) when the drive mechanism is actuated once more for setting and delivering a further dose. Also, a piston rod (3) is proposed.

  • DRUG DELIVERY SYSTEM

    The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-.beta.) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen

  • FREQUENCY MODULATED DRUG DELIVERY (FMDD)

    Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties.

  • DRUG DELIVERY FROM EMBOLIC AGENTS

    An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 .mu.m and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.

  • TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING

    A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

  • CERAMIDE ANIONIC LIPOSOME COMPOSITIONS

    Described herein are pharmaceutical compositions according to aspects of the present invention which include one or more hydrophilic antineoplastic chemotherapeutics, such as vinca alkyloid antineoplastic chemotherapeutics, encapsulated in ceramide anionic liposomes. Methods of treatment of a subject having cancer using the pharmaceutical compositions are described, along with methods of making ceramide anionic liposomes which encapsulate one or more hydrophilic antineoplastic chemotherapeutics in the aqueous interior of the ceramide anionic liposomes.

  • LIPOSOME OF IRINOTECAN OR ITS HYDROCHLORIDE AND PREPARATION METHOD THEREOF

    A liposome of irinotecan or irinotecan hydrochloride and its preparation method are disclosed. The liposome contains irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:3 to 1:5. The liposome is prepared by an ion gradient method.

  • LIPOSOME COMPOSITION FOR TARGETING EGFR RECEPTOR

    Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.

  • NJECTABLE DRUG DELIVERY ARRANGEMENT WITH CONTROLLED DELIVERY CANNULA POSITION RELATIVE TO POINT OF DELIVERY

    A cannula for administration of a medicine to a target location includes a tube with at least one nodule disposed along the circumferential surface and spaced at a defined distance from the distal end of the tube. An arrangement for delivery of a medicine to a target location includes the cannula and a pump fluidly coupled to the cannula. The distal end of the cannula may be inserted into a target location until the nodule reaches a surface that limits a depth of penetration before delivery of the medication.

  • FLUID DRUG DELIVERY SYSTEM AND METHOD FOR MANUFACTURING A DRUG DELIVERY SYSTEM

    A fluid drug delivery system comprises a rigid shell having an inner sidewall, an opening and a passage as well as a collapsible cartridge with a distal end and a proximal end. The collapsible cartridge is arranged within the shell with its distal end being closer to the opening than the proximal end. It further comprises a first portion including the proximal end and a second portion including the distal end. The second portion is recoilable from the inner sidewall to urge a fluid, which comprises a drug and is contained in the collapsible cartridge, to the passage of the rigid shell. Further, the rigid shell and the collapsible cartridge are co-extruded.

  • SUSTAINED-RELEASE RESERVOIR IMPLANTS FOR INTRACAMERAL DRUG DELIVERY

    The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.

  • COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY

    Here described are compounds consisting of the structure (targeting molecule).sub.m-linker-(targeting molecule).sub.n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

  • PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF

    Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.

  • PHARMACOLOGICALLY OPTIMIZED MULTIMODAL DRUG DELIVERY SYSTEM FOR NORDIHYDROGUIARETIC ACID (NDGA)

    The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

  • METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES

    The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu.sup.22,25, Leu.sup.23,28,31, Aib.sup.29, Lys.sup.26,30]hPTHrP(1-34)NH.sub.2.

  • METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH

    Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R.sub.T), having an affinity for bone; a Bone Active Portion (R.sub.A) for interacting with and affecting bone; and a Linking Portion (R.sub.L) connecting the Bone Targeting Portion and the Bone Active Portion.

  • TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES

    The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers.

  • Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery

    The present invention provides methods and compositions to selectively and directly deliver nanoparticles carrying an active agent to tumor cells. The active agent is internalized by the tumor cells, producing an anti-tumor effect for therapeutic applications and/or depositing a detectable marker for diagnostic applications. The present invention further provides a p53 chimera that circumvents the dominant negative activity of mutant p53 as a therapeutic in the treatment of cancer and reduction of mor size.

  • DRUG DELIVERY ENDOVASCULAR STENT AND METHOD OF USE

    An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 .mu.in (0.5 .mu.m) and a surface roughness range of between about 300-700 .mu.in (7.5-17.5 .mu.m). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface.

  • Dentinal Drug Delivery Composition

    The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent and a method for using the same to provide a dental treatment.

  • LOGICAL ENZYME TRIGGERED (LET) LAYER-BY-LAYER NANOCAPSULES FOR DRUG DELIVERY SYSTEM

    Nanocapsule compositions comprising a calcium carbonate core surrounded by a bilayer or bilayers of polystyrene sulfonate and poly(allylamine hydrochloride). The poly(allylamine hydrochloride) is conjugate to a substrate, wherein the substrate is capable of being acted upon (for example cleaved) by a biomarker or enzyme associated with a disease state of interest. The nanocapsule compositions may be administered to an animal, for example a human, for the treatment of a disease state.

  • IN SITU GELLING DRUG DELIVERY SYSTEM

    The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

  • TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DONEPEZIL

    The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.

  • Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead

    A modular capsule includes a first therapeutic agent having a first solubility in biological fluids in an implanted environment and a second therapeutic agent having a second lower solubility in the biological fluids. The modular capsule is configured such that dissolution of the first therapeutic agent increases a rate of dissolution of the second therapeutic agent.

  • DRUG DELIVERY SYSTEM

    The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.

  • MICROJET DRUG DELIVERY SYSTEM AND MICROJET INJECTOR

    The present invention relates to a microjet drug delivery system for microjet spraying a drug solution stored inside to inject the same into the bodily tissue of a person to be operated, and a microjet injector. The microjet injector comprises: a pressure chamber completely filled with the liquid for propelling pressure, having an accommodation space with one side opened; an elastic film, which is a film member made of an elastic material, arranged so as to form a closed space by closing the opened one side of the pressure chamber; a drug chamber for accommodating a drug solution in a predetermined inner space, provided adjacent to the pressure chamber with interposing the elastic film therebetween; and a microjet nozzle communicating with the inner space of the pressure chamber so as to be formed as a channel for allowing the drug solution stored inside the pressure chamber to be microjet sprayed to the outside. The microjet drug delivery system provided by the present invention comprises: the microjet injector; an energy focusing device for generating bubbles in the liquid for propelling pressure stored in the pressure chamber by applying a concentrated energy to the liquid for propelling pressure; and a connecting adaptor for selectively detachably coupling the microjet injector to the energy focusing device.

  • LIPOSOMES FOR THE ORAL DELIVERY OF THERAPEUTIC AGENTS

    The invention relates to liposomes having membranes composed of amphipathic molecules and long chain lipids in ratios that are proportionately higher in amphipathic molecules. Such ratios enhance the enzymatic breakdown of the inventive liposomes thereby improving the bioavailabity of encapsulated substances for oral delivery. Compositions of liposomes and methods of their use and manufacture are within the scope of the invention.

  • RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION

    What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1.sub.--2 (SEQ ID NOS: 60 and 127), SERPINH1.sub.--45a (SEQ ID NOS: 98 and 165), and SERPINH1.sub.--51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.

  • DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES

    The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.

  • LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS

    The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).

  • RADIATION SENSITIVE LIPOSOMES

    The present invention relates to a radiation sensitive liposome, and the use of this liposome as carrier for therapeutic and diagnostic agent(s). In particular, the invention encompasses a liposomal delivery system, comprising a stable liposome-forming lipid and a polymerizable colipid, a fraction of which polymerizable colipid polymerizes upon exposure to ionizing radiation, thereby destabilizing the liposomal membrane. Destabilization of liposomes allows for leakage of liposomal contents. The present invention further contemplates methods of diagnosing and treating conditions and diseases that are responsive to liposome-encapsulated or associated agents.

  • LIPOSOMES COMPRISING AMPHIPATHIC DRUGS AND METHOD FOR THEIR PREPARATION

    The present invention provides a liposome having co-encapsulated in its intraliposomal aqueous core at least two amphipathic drugs, the liposomes being characterized by one of the following: the amphipathic drugs are co-encapsulated at a pre-determined ratio; the liposome comprises one or a combination of liposome forming lipids have a solid ordered to liquid disordered phase transition temperature above 37.degree. C.; each of the amphipathic drugs exhibit a liposomal profile that corresponds to the profile of each drug when encapsulated as a single drug in the same liposome; and the liposome is absent of one or both of a transition metal and a ionophore. The invention also provides a method for preparing such liposomes. This method, taken together with the features of the liposomal composition, provides high loading and long term stability of the resulting co-encapsulated liposomal formulation.

  • DISPERSION OF CARBONACEOUS NANOPARTICLES AND METHOD OF MAKING THE SAME

    A dispersion includes a carbonaceous nanoparticle, a dispersant including a graft polymer having a poly(alkylene glycol) side chain, and a polar solvent. An article coated with the dispersion and a method of making the dispersion are disclosed.

  • MULTI-LEG LUMINESCENT NANOPARTICLES, MULTI-LEG LUMINESCENT NANOPARTICLE COMPOUNDS AND VARIOUS APPLICATIONS

    Multi-leg luminescent nanoparticles ("MLN's") that can be paired to other MLN's as well s biological molecules to film branched multi-leg luminescent nanoparticles ("BMLN's) that can be used in biological multiplexing applications, imaging applications, biological detection applications and other biological applic ations.

  • AQUEOUS DISPERSIONS OF POLYURETHANE AND NANOPARTICLES

    The present disclosure is directed to aqueous dispersions comprising polyurethane and nanoparticles, and processes for preparing the aqueous dispersions. The dispersions comprise aqueous polyurethane dispersions having nanoparticles covalently incorporated into the polymer matrix. The dispersions are prepared by reacting isocyanate groups present on the polyurethane chain ends with free amine groups on a hydroxy- or amino-functionalized nanoparticle to covalently attach the polyurethane and the nanoparticle through urethane or urea linkages, respectively.

  • NANOPARTICLES AND NANOPARTICLE COMPOSITIONS

    The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

  • POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE

    A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye.

  • MYOCARDIAL DRUG DELIVERY APPARATUS AND METHOD

    Embodiments provide apparatus and methods for delivering solid form drug (SFD) to various locations in the body. In one embodiment, the invention provides an apparatus for treatment of arrhythmia comprising a drug delivery member (DDM) coupled to a drug storage device (DSD). The DSD is configured to store and advance SFD (e.g., drug pellets) through the DDM to a target tissue site (TTS) in or on the heart. A drug advancement member may be used to advance the SFD through the DSD. A capture chamber (CC) may be coupled to the DDM. and is configured to be positioned on a heart surface and allow SFD to dissolve to deliver a drug solution to the heart. The DSD can be implanted subcutaneously e.g., in the pectoral area. Embodiments of the apparatus can be used to store and deliver SFD to the heart or other TTS over an extended period of years.

  • LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY

    The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2.mu..pi.. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

  • Balloon Catheter Systems for Delivery of Dry Drug Delivery Vesicles to a Vessel in the Body

    Devices and methods for balloon delivery of rapamycin and other hydrophobic compounds to the wall of blood vessels. Balloon catheters, such as those used for balloon angioplasty, are modified with the addition of a reservoir of dry micelles, disposed at a suitable location within the balloon or catheter. The reservoir may be installed within the angioplasty balloon, within a lumen in communication with the angioplasty balloon, either as a loose or packed powder or as a film coating. The micelle preparation is reconstituted and the micelles are mobilized when the aqueous solution used to inflate the balloons is injected into the catheter. The micelles are infused into tissue surrounding the balloon when pressurized fluid within the balloon leaks through the wall of the balloon.

  • FOAMS OR PARTICLES FOR APPLICATIONS SUCH AS DRUG DELIVERY

    The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02. For example, a precursor to the foam, containing a pharmaceutically active agent, may be mixed with a foaming agent, then the pressure decreased to cause the foaming agent to expand, thereby causing a foam to form. The foam may then be subsequently ground or milled, or otherwise processed to form particles.

  • DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY

    A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.

  • POLYMERIC MICELLES FOR DRUG DELIVERY

    The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.

  • THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

    Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

  • DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF

    Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO.sub.2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO.sub.2 in their environment, thus regulating release of an entrapped drug.

  • TOPICAL DRUG DELIVERY SYSTEM WITH DUAL CARRIERS

    An over-the-counter (OTC) regulated therapeutic composition for self-medication use for application to wounds having a potential pathogen load, in which the composition comprises a tissue penetration enhancer comprising a Class I pharmaceutical incipient; a pharmaceutical antibiotic agent in a dosing suitable for use in an OTC listing; a hygroscopic carrier agent comprising a Class I pharmaceutical incipient suitable for mixing in solution with the tissue penetration enhancer and the antibiotic agent; and wherein the activity/water (A.sub.W) measurement of the composition is less than the A.sub.w measurement for a target pathogen in a tissue wound.

  • LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY

    The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2.mu..pi.. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceuticalcomposition to a subject in need thereof.

  • PERCUTANEOUS ABSORPTION TYPE FORMULATION

    Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.

  • PERCUTANEOUS ABSORPTION TYPE FORMULATION

    Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.

  • TOPICAL OPHTHALMIC PEPTIDE FORMULATION

    A topical ophthalmic formulation of peptides and their use for the treatment and/or local prevention of ocular diseases, preferably posterior segment eye diseases.

  • SWELLABLE PARTICLES FOR DRUG DELIVERY

    Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 .mu.m, the particles being swellable by hydration to a size that is greater than 6 .mu.m volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.

  • NOVEL CONJUGATES FOR TARGETED DRUG DELIVERY

    The present invention relates to a novel drug delivery system comprising a drug(s)-protein-polymer triple conjugate. The triple conjugate employs a (i) protein moiety capable of binding selectively to a particular target site possessed by a cell/affected organ, (ii) a polymer moiety, covalently linked to the protein and (iii) an active drug moiety that includes one or more drug(s) covalently linked to either said polymer moiety or to a protein moiety. The conjugates of the present invention have target specificity and better selectivity to a defined population of cells/organs(s). The present invention further relates to methods of preparation and methods of treatment comprising administering said conjugate as a single unit. The conjugates of the present invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic applications.

  • Drug Delivery Dispersion And Film Formed Therefrom

    An active agent delivery dispersion includes water, 1 to 98 weight percent of a plurality of encapsulated particles dispersed in the water, and 0.1 to 20 weight percent of an active agent, each based on a total weight of the dispersion. The active agent is dispersed in the water independently from the plurality of encapsulated particles. Each of the particles includes a core and a layer including a silica disposed about the core. The plurality includes first and second populations of encapsulated particles. The core of the first population includes a first organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule and a hydro-silylation catalyst. The core of the second population includes an organohydrogensiloxane having an average of greater than two silicon bonded hydrogen atoms per molecule and a second organopolysiloxane having at least two silicon-bonded alkenyl groups per molecule

  • PHARMACOLOGICALLY OPTIMIZED MULTIMODAL DRUG DELIVERY SYSTEM FOR NORDIHYDROGUIARETIC ACID (NDGA)

    The present invention relates generally to compositions and methods for oral delivery of nordihydroguaiaretic acid (NDGA). More particularly, the present invention relates to pharmacologically optimized multimodal drug delivery systems for orally administered NDGA and methods for preparation and use thereof.

  • LIPOSOMES CONTAINING PERMEATION ENHANCERS FOR ORAL DRUG DELIVERY

    The present invention relates to liposomal compositions and their application for delivery of pharmaceuticals for the treatment of disease.

  • DRUG DELIVERY TECHNOLOGY

    The present invention relates to novel drug delivery technology in the form of solid dose injection devices and methods which utilise a blade that is pushed into the skin to a predetermined depth before the before a solid drug formulation is pushed into the cut made by the blade. Thus the present invention also relates to delivering a therapeutic compound to a human or animal in the form of a solid dose injection comprising: providing an injection device comprising a casing; an actuation mechanism capable of ei generating a force, a blade, a solid drug formulation; and a means for pushing said solid drug formulation; wherein the blade is inser ted to a predetermined depth in the skin and, following insertion of the blade, the device is actuated such that the actuation mechanism capable of generating a force acts on the means for pushing to push the solid drug formulation out of the casing and into the human or animal body.

  • METHOD OF DRUG DELIVERY BY CARBON NANOTUBE CHITOSAN NANOCOMPLEXES

    Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells.

  • DRUG DELIVERY SYSTEM AND METHODS OF TREATING OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

  • POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM

    Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the polymer matrix. Advantageously, the polymer is permeable to the agent and is non-release-rate-limiting with respect to the rate of release of the agent from the polymer.

  • LIPID NANO PARTICLES COMPRISING CATIONIC LIPID FOR DRUG DELIVERY SYSTEM

    The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R.sup.1 and R.sup.2 are, the same or different, alkenyl, etc, and X.sup.3 is absent or is alkyl, etc, X.sup.1 and X.sup.2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and Y.sup.1 is absent or anion, L.sup.1 is a single bond, etc, R.sup.3 is alkyl, etc), and the like. ##STR00001##

  • ELECTRONIC ASSEMBLY FOR IONTOPHORESIS TRANSDERMAL DRUG DELIVERY AND DEVICE THEREOF

    An electronic assembly for iontophoresis transdermal delivery of at least one drug includes an input mechanism configured to receive at least one parameter for iontophoresis transdermal delivery of the at least one drug. The electronic assembly further includes a controller configured to select current intensity and a voltage modulation based on the at least one parameter. The controller is further configured to generate a voltage waveform based on the selected current intensity for a drug delivery period.

  • METHOD FOR CONTROLLING DRUG DELIVERY THROUGH AN INFUSION SET

    A slide clamp for use with an infusion pump and infusion set provides finger grips and support members for supporting the infusion tubing. The finger grips make the slide clamp easier to use while reducing the risk of error. The tubing support members reduce the likelihood of improperly loading the tubing and reduce the risk of kinking the tubing during use. An infusion set is provided wherein the slide clamp may be coded through the use of colors, holes, or the like so as to identify the type of infusion tubing used therewith. The infusion pump can identify the code on the slide clamp and thereby determine the type of infusion tubing, and thereby allow access only to infusion programs for drugs or infusion solutions which are compatible with the particular type of infusion tubing.

  • THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM

    The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.